New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
10:35 EDTLLYEli Lilly drops after cancer drug data seen as 'underwhelming'
Eli Lilly (LLY) is retreating after the company reported a median overall survival rate of 5.2 months for patients who received the company's gastric cancer treatment, ramucirumab, in an abstract posted last night on the American Society of Clinical Oncology’s website. Patients who received a placebo had a median overall survival rate of 3.8 months. Although the overall survival rate produced by the drug was statistically significant, Leerink Swann analyst Seamus Fernandez called the data "somewhat underwhelming" in a note to investors earlier today. The company may still seek FDA approval for ramucirumab, but the agency will likely require the company to conduct another study before it will approve the drug, the analyst believes. Fernandez maintained an Outperform rating on the stock, which slid $1.10 ,or 2.06%, to $52.34 in mid-morning trading.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
12:16 EDTLLYEli Lilly and Bristol-Myers restructure Erbitux collaboration in N. America
Subscribe for More Information
April 15, 2015
07:41 EDTLLYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 10, 2015
11:03 EDTLLYEli Lilly granted orphan status for anal cancer treatment
Subscribe for More Information
April 9, 2015
09:25 EDTLLYPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 7, 2015
07:14 EDTLLYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
07:14 EDTLLYBiodel GEM device demonstrates 'superior' usability
Biodel (BIOD) announced results from a formative human factors study of its Glucagon Emergency Management, or GEM, device, which is in development for the treatment of diabetes patients experiencing severe hypoglycemia. In the study, the GEM device demonstrated a substantial improvement in ease-of-use and successful delivery of the full dose, as well as a reduction in dosing errors, when compared to commercially available glucagon kits; Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit. Furthermore, while training and previous experience increased the success rate with the Eli Lilly and Novo Nordisk glucagon kits, it did not further impact the already high success rate with the GEM device when compared to non-experienced, untrained participants.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use